CAMBRIDGE, Mass., May 20, 2026
MetaVia Inc. has announced the publication of new peer-reviewed preclinical research supporting the anti-fibrotic potential of vanoglipel (DA-1241), the company’s investigational GPR119 agonist being developed for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and type 2 diabetes. The findings, published in the international scientific journal Biomolecules & Therapeutics, strengthen growing scientific evidence that GPR119 signaling may represent a differentiated therapeutic pathway capable of addressing both metabolic dysfunction and liver fibrosis progression.
The publication, titled “A Novel Anti-Fibrotic Role of G-Protein-Coupled Receptor 119 in Hepatic Stellate Cells,” demonstrated that GPR119 agonists reduced liver fibrosis and suppressed biological pathways associated with scar tissue formation in the liver. Researchers believe the study provides important mechanistic support for vanoglipel’s therapeutic potential as a next-generation treatment candidate targeting chronic liver disease and metabolic dysfunction.
Industry analysts note that the findings arrive at a time of rapidly growing global focus on MASH therapies as pharmaceutical companies race to develop effective treatments for liver fibrosis, obesity-related metabolic disease, and chronic inflammation.
Vanoglipel Shows Encouraging MASH and Fibrosis Signals
MASH, previously known as nonalcoholic steatohepatitis (NASH), is a progressive liver disease characterized by fat accumulation, inflammation, fibrosis, and eventual liver damage. The condition is closely associated with obesity, insulin resistance, type 2 diabetes, and cardiometabolic disorders, creating major healthcare burdens worldwide.
Advertisement
MetaVia stated that vanoglipel acts as a G-Protein-Coupled Receptor 119 (GPR119) agonist, promoting release of key gut peptides including GLP-1, GIP, and PYY, which are involved in glucose regulation, lipid metabolism, weight control, and inflammatory signaling. According to the company, the compound has demonstrated beneficial metabolic and hepatic effects across multiple preclinical studies evaluating MASH and type 2 diabetes.
The newly published data showed that activation of the GPR119 pathway may directly reduce fibrotic progression within hepatic stellate cells, which play a central role in liver scar tissue formation. Researchers highlighted the possibility that vanoglipel’s combined metabolic and anti-fibrotic mechanisms could differentiate the therapy from other MASH treatment strategies currently under development.
MetaVia executives emphasized that the preclinical findings align with observations from the company’s earlier Phase 2a clinical study, where patients receiving vanoglipel experienced statistically significant reductions in ALT levels and the serum fibrosis marker TIMP1, alongside favorable trends in liver fibrosis measurements using VCTE imaging.
Growing Demand for Effective MASH Therapies
Healthcare experts increasingly view MASH as one of the most urgent unmet medical needs in hepatology and metabolic disease medicine due to its rising prevalence and lack of widely effective treatment options. The disease can progress to advanced fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma if left untreated.
The global MASH treatment market has attracted substantial pharmaceutical investment over the past decade as obesity rates, diabetes prevalence, and metabolic syndrome cases continue increasing worldwide. Industry researchers believe therapies capable of addressing both metabolic dysfunction and fibrosis progression may offer important competitive advantages in future treatment landscapes.
MetaVia noted that vanoglipel also demonstrated improvements in liver fat reduction, glucose control, and overall tolerability during clinical testing, reinforcing its broader cardiometabolic therapeutic potential. The company believes the consistency between mechanistic laboratory data and early clinical observations strengthens confidence in the compound’s future development pathway.
Researchers additionally highlighted the possibility of developing vanoglipel as both a standalone therapy and as part of future combination treatment approaches for MASH and metabolic liver disease.
Cardiometabolic Drug Development Continues Accelerating
MetaVia is currently advancing a broader pipeline of investigational cardiometabolic therapies targeting obesity, diabetes, and liver disease. In addition to vanoglipel, the company is developing DA-1726, a dual GLP-1 receptor and glucagon receptor agonist for obesity treatment that recently demonstrated encouraging weight-loss potential in early-stage clinical trials.
Industry analysts believe the convergence of obesity medicine, metabolic disease treatment, and liver fibrosis research is rapidly reshaping pharmaceutical development priorities. As healthcare systems face rising cardiometabolic disease burdens, demand for innovative therapies addressing interconnected metabolic pathways is expected to increase significantly.
MetaVia stated that the latest publication provides additional scientific validation supporting ongoing development of vanoglipel for MASH and related metabolic disorders. Experts believe future late-stage clinical trials will be closely watched as companies compete to establish leadership positions within the emerging MASH therapeutics market.
Source: MetaVia press release
